Back to Search Start Over

Clinical Features of Critically Ill Patients With Shiga Toxin–Induced Hemolytic Uremic Syndrome

Authors :
Tobias N. Meyer
Matthias Müller-Schulz
Karl Wegscheider
Stefan Kluge
Jens Fiehler
Marie C. von Heinz
Andreas de Weerth
Wilhelm-W. Hoepker
Jens Fricke
Ulf Panzer
Christian Gerloff
Stephan Braune
Gerd P. Meyer
Heinrich Becker
Dominic Wichmann
Tim Magnus
Rolf A.K. Stahl
Axel Nierhaus
Source :
Critical Care Medicine. 41:1702-1710
Publication Year :
2013
Publisher :
Ovid Technologies (Wolters Kluwer Health), 2013.

Abstract

Objective In Spring 2011, an unprecedented outbreak of Shiga toxin-producing Escherichia coli serotype O104:H4-associated hemolytic uremic syndrome occurred in Northern Germany. The aim of this study was to describe the clinical characteristics, treatments, and outcomes of critically ill patients with Shiga toxin-producing E. coli-associated hemolytic uremic syndrome during this outbreak. Design, setting, and patients Multicenter, retrospective, observational study of critically ill adult patients with Shiga toxin-producing E. coli-associated hemolytic uremic syndrome in six hospitals in Hamburg, Germany, between May 2011 and August 2011. Measurements and main results During the study period, 106 patients with Shiga toxin-producing E. coli-associated hemolytic uremic syndrome were admitted to eight ICUs. The median age was 40 years (range, 18-83) with a female:male ratio of 3:1. The median time from onset of clinical symptoms to hospital admission was 3 days and from hospital to ICU admission an additional 3 days. A total of 101 patients (95.3%) had acute renal failure and 78 (73.6%) required renal replacement therapy. Intubation and mechanical ventilation were required in 38 patients (35.8%) and noninvasive ventilation was required in 17 patients (16.0%). The median duration of invasive ventilation was 7 days (range, 1-32 days) and the median ICU stay was 10 days (range, 1-45 days). Fifty-one patients (48.1%) developed sepsis; of these 51 patients, 27 (25.4%) developed septic shock. Seventy patients (66.0%) developed severe neurological symptoms. Ninety-seven patients (91.5%) were treated with plasma exchange and 50 patients (47.2%) received eculizumab (monoclonal anti-C5 antibody). The mortality rate was 4.7%. Mild residual neurological symptoms were present in 21.7% of patients at ICU discharge, and no patient required renal replacement therapy 6 months after ICU admission. Conclusions During the 2011 Shiga toxin-producing E. coli-associated hemolytic uremic syndrome outbreak in Germany, critical illness developed rapidly after hospital admission, often in young women. The infection was associated with severe neurological and renal symptoms, requiring mechanical ventilation and renal replacement therapy in a substantial proportion of patients. Overall, recovery was much better than expected.

Details

ISSN :
00903493
Volume :
41
Database :
OpenAIRE
Journal :
Critical Care Medicine
Accession number :
edsair.doi.dedup.....c475f2ba6e0247af9fa5e9b52495ae8f